Consensus
The community sees this as very unlikely for AstraZeneca at 24%, based on 5 forecasts. Forecasters are in moderate agreement.
Resolves YES if AstraZeneca is down more than 32% 12 months out versus its baseline price.
Share your read on this question — the best forecasters show their work.
See the whole azn discussion →